Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Publisher: La Merie Publishing
Pages: 26
Format: PDF
Product Line:
Target Pipeline
Product Line:
Competitor Analysis
Product Code: LMCA0166
Release Date: March of 2018

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

This Competitive Intelligence report about CDK9 and Mcl1 Inhibitors provides a competitor evaluation in the field of inhibitors of CDK9 and Mcl-1 as of March 2018.
Cyclin-dependent kinase 9 (CDK9) regulates elongation of transcription through phosphorylation of RNA polymerase II (pSer2-RNAPII), and its short-term inhibition results in the selective downregulation of genes with short-lived transcripts and labile proteins - including the „pro-survival“ protein Mcl1.

Myeloid Cell Leukaemia-1 (Mcl-1), an anti-apoptotic member of the Bcl-2 protein family, has emerged as an especially attractive target for the development of next generation antineoplastics owing to its direct involvement in tumor genesis as well as its role in the resistance of many cancers to current anti-cancer therapies.

The report includes a compilation of currently active projects in research and development of small molecule and biologic inhibitors of CDK9 or Mcl-1. In addition, the report lists company- and institution-specific R&D pipelines of CDK9 and Mcl-1 inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Table of Contents

1)        CDK9 and Mcl-1 Inhibitors

  • Cyclin-Dependent Kinase 9 (CDK9) Inhibitors
  • Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors

2)        Corporate CDK9 & Mcl-1 Inhibitor R&D Pipelines


 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top